Benjamin L. Woolbright

Pharmacology, Toxicology and PharmaceuticsBiochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 8 papers. Top paper: “Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes”.

Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes

Nature Reviews Urology(2020)10.1038/s41585-020-0304-1

N/A

0.794DataRank · unranked

198 citations

Hikmat Al‐Ahmadie, Bishoy M. Faltas, John A. Taylor, Thomas W. Flaig, David J. DeGraff +5 more

Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the γ-secretase complex

Cell Death and Disease(2021)10.1038/s41419-021-03836-z

N/A

0.633DataRank · unranked

14 citations

Prasad Dandawate, David Standing, Sangita Bhattacharyya, Prabhu Ramamoorthy, Parthasarathy Rangarajan +13 more

4-Methylpyrazole-mediated inhibition of cytochrome P450 2E1 protects renal epithelial cells, but not bladder cancer cells, from cisplatin toxicity

Toxicological Sciences(2025)10.1093/toxsci/kfaf053

N/A

0.241DataRank · unranked

4 citations

Erika Abbott, Benjamin L. Woolbright, Anup Ramachandran, Rick G. Schnellmann, Darren P. Wallace +2 more

Fosciclopirox clinical proof of concept in patients with nonmuscle invasive and muscle-invasive bladder cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e16557

N/A

0.165DataRank · unranked

2 citations

Elizabeth R. Kessler, Janet Baack Kukreja, Gerald S. Falchook, Manojkumar Bupathi, Rahul Atul Parikh +15 more

Understanding the microbiome as a mediator of bladder cancer progression and therapeutic response

Urologic Oncology Seminars and Original Investigations(2024)10.1016/j.urolonc.2024.07.004

N/A

0DataRank · unranked

2 citations

John A. Taylor, Benjamin L. Woolbright, Mahgol Golshani

IV vitamin C with chemotherapy for cisplatin ineligible bladder cancer patients (CI-MIBC) first-stage analysis NCT04046094.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e16540

N/A

0DataRank · unranked

2 citations

John A. Taylor, Qi Chen, Benjamin L. Woolbright, Ping Chen, Elizabeth Wulff‐Burchfield +4 more

Late Protective Effect of Netrin-1 in the Murine Acetaminophen Hepatotoxicity Model

Toxicological Sciences(2020)10.1093/toxsci/kfaa041

N/A

0DataRank · unranked

21 citations

Benjamin L. Woolbright, Hartmut Jaeschke, Anup Ramachandran, Luqi Duan

Loss of MK2 Enhances Radiation-Mediated Apoptosis in Bladder Cancer

World Journal of Oncology(2024)10.14740/wjon1945

N/A

0DataRank · unranked

0 citations

Kiersten L. Berggren, Grace Millington, Hanna Smith, Colby Spiess, M.D. Hixon +7 more